Xenon: Epilepsy Got It To $59; Depression Has To Take It From Here (NASDAQ:XENE)
· seekingalpha.com
Xenon’s Phase 3 azetukalner cut focal seizures by 53%, and FDA filing nears. Click for more on XENE stock.
At $59, I would not buy Xenon Pharmaceuticals Inc. (NASDAQ: XENE ) for its upcoming FDA filing. The filing is expected. The stock already carries a market value...